Literature DB >> 16254312

ASCOT: a tale of two treatment regimens: is ASCOT all it's cracked up to be?

James A Cave.   

Abstract

Mesh:

Substances:

Year:  2005        PMID: 16254312      PMCID: PMC1273465          DOI: 10.1136/bmj.331.7523.1023

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  4 in total

1.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Authors:  Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

2.  ASCOT: a tale of two treatment regimens.

Authors:  Claire McDougall; Adrian J B Brady; John R Petrie
Journal:  BMJ       Date:  2005-10-15

3.  Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).

Authors:  Neil R Poulter; Hans Wedel; Björn Dahlöf; Peter S Sever; D Gareth Beevers; Mark Caulfield; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren; Stuart Pocock
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

4.  Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials.

Authors:  M Pahor; B M Psaty; M H Alderman; W B Applegate; J D Williamson; C Cavazzini; C D Furberg
Journal:  Lancet       Date:  2000-12-09       Impact factor: 79.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.